Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
IMGN's Cash to Debt is ranked higher than
86% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. IMGN: No Debt )
IMGN' s 10-Year Cash to Debt Range
Min: 0.39   Max: 50356.33
Current: No Debt

0.39
50356.33
Equity to Asset 0.53
IMGN's Equity to Asset is ranked higher than
63% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IMGN: 0.53 )
IMGN' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.95
Current: 0.53

0.27
0.95
Interest Coverage No Debt
IMGN's Interest Coverage is ranked higher than
78% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMGN: No Debt )
IMGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 2.00
M-Score: -3.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -205.46
IMGN's Operating margin (%) is ranked higher than
64% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. IMGN: -205.46 )
IMGN' s 10-Year Operating margin (%) Range
Min: -3860   Max: -6.81
Current: -205.46

-3860
-6.81
Net-margin (%) -204.90
IMGN's Net-margin (%) is ranked higher than
65% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. IMGN: -204.90 )
IMGN' s 10-Year Net-margin (%) Range
Min: -3980   Max: -2.13
Current: -204.9

-3980
-2.13
ROE (%) -59.76
IMGN's ROE (%) is ranked higher than
60% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. IMGN: -59.76 )
IMGN' s 10-Year ROE (%) Range
Min: -611.11   Max: -1.55
Current: -59.76

-611.11
-1.55
ROA (%) -34.09
IMGN's ROA (%) is ranked higher than
66% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. IMGN: -34.09 )
IMGN' s 10-Year ROA (%) Range
Min: -194.12   Max: -1.23
Current: -34.09

-194.12
-1.23
ROC (Joel Greenblatt) (%) -677.08
IMGN's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. IMGN: -677.08 )
IMGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -677.08   Max: -50.46
Current: -677.08

-677.08
-50.46
Revenue Growth (%) 20.50
IMGN's Revenue Growth (%) is ranked higher than
90% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. IMGN: 20.50 )
IMGN' s 10-Year Revenue Growth (%) Range
Min: -36.1   Max: 133.1
Current: 20.5

-36.1
133.1
EBITDA Growth (%) 0.80
IMGN's EBITDA Growth (%) is ranked higher than
81% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. IMGN: 0.80 )
IMGN' s 10-Year EBITDA Growth (%) Range
Min: -71.2   Max: 282.6
Current: 0.8

-71.2
282.6
» IMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

IMGN Guru Trades in Q2 2013

PRIMECAP Management 12,507,427 sh (unchged)
» More
Q3 2013

IMGN Guru Trades in Q3 2013

Steven Cohen 10,452 sh (New)
PRIMECAP Management 12,601,727 sh (+0.75%)
» More
Q4 2013

IMGN Guru Trades in Q4 2013

PRIMECAP Management 12,675,427 sh (+0.58%)
Steven Cohen Sold Out
» More
Q1 2014

IMGN Guru Trades in Q1 2014

PRIMECAP Management 12,675,427 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with IMGN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.40
IMGN's P/B is ranked higher than
62% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. IMGN: 9.40 )
IMGN' s 10-Year P/B Range
Min: 1.68   Max: 16.19
Current: 9.4

1.68
16.19
P/S 16.00
IMGN's P/S is ranked higher than
73% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. IMGN: 16.00 )
IMGN' s 10-Year P/S Range
Min: 2.83   Max: 97.63
Current: 16

2.83
97.63
EV-to-EBIT -12.03
IMGN's EV-to-EBIT is ranked lower than
54% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IMGN: -12.03 )
IMGN' s 10-Year EV-to-EBIT Range
Min: 105.1   Max: 606
Current: -12.03

105.1
606
Current Ratio 8.13
IMGN's Current Ratio is ranked higher than
86% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. IMGN: 8.13 )
IMGN' s 10-Year Current Ratio Range
Min: 0.51   Max: 60.86
Current: 8.13

0.51
60.86
Quick Ratio 8.01
IMGN's Quick Ratio is ranked higher than
86% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. IMGN: 8.01 )
IMGN' s 10-Year Quick Ratio Range
Min: 0.51   Max: 60.86
Current: 8.01

0.51
60.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.40
IMGN's Price/Net Cash is ranked higher than
81% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. IMGN: 12.40 )
IMGN' s 10-Year Price/Net Cash Range
Min: 0.9   Max: 179
Current: 12.4

0.9
179
Price/Net Current Asset Value 12.00
IMGN's Price/Net Current Asset Value is ranked higher than
80% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. IMGN: 12.00 )
IMGN' s 10-Year Price/Net Current Asset Value Range
Min: 0.88   Max: 58.33
Current: 12

0.88
58.33
Price/Tangible Book 9.60
IMGN's Price/Tangible Book is ranked higher than
69% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. IMGN: 9.60 )
IMGN' s 10-Year Price/Tangible Book Range
Min: 0.81   Max: 40
Current: 9.6

0.81
40
Price/Median PS Value 1.00
IMGN's Price/Median PS Value is ranked higher than
83% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. IMGN: 1.00 )
IMGN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 9.3
Current: 1

0.2
9.3
Earnings Yield (Greenblatt) 0.50
IMGN's Earnings Yield (Greenblatt) is ranked lower than
61% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. IMGN: 0.50 )
IMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 1
Current: 0.5

0.2
1
Forward Rate of Return (Yacktman) -1.88
IMGN's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. IMGN: -1.88 )
IMGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -20   Max: -3.7
Current: -1.88

-20
-3.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IMU.Germany
Immunogen, Inc. was organized as a Massachusetts corporation in 1981. The Company develops antibody-based anticancer therapeutics. All of its wholly owned clinical and preclinical product candidates are antibody-drug conjugates, or ADCs, which use a monoclonal antibody to deliver a small molecule to targeted cells. The Company develops its its own product candidates using its TAP technology with antibodies from its research programs. The Company has four wholly owned, clinical-stage anticancer compounds—IMGN901, IMGN853, IMGN289, and IMGN529. The Company also has license to other companies limited rights to use its technology with their antibodies to create products. The advanced compound with its TAP technology is Kadcyla which was launched in the U.S.and Switzerland. Its manufacturing facility is in Norwood, Massachusetts.
» More Articles for IMGN

Headlines

Articles On GuruFocus.com
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial Results Aug 06 2009 
ImmunoGen Inc. Reports Operating Results (10-Q) May 07 2009 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 06 2009 

More From Our Partners
ImmunoGen (IMGN) Soars: Stock Up 8.8% - Tale of the Tape Jul 21 2014 - ZACKS

More From Other Websites
Nasdaq stocks posting largest percentage decreases Jul 24 2014
Stock To Watch: Immunogen (IMGN) In Perilous Reversal Jul 21 2014
ImmunoGen (IMGN) Soars: Stock Up 8.8% Jul 21 2014
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2014... Jul 18 2014
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2014... Jul 18 2014
ImmunoGen receives orphan status for ovarian cancer treatment Jul 15 2014
Shares Of ImmunoGen Down On Morgan Stanley's Bearish Initiation Jun 25 2014
IMMUNOGEN INC Files SEC form 8-K, Other Events Jun 17 2014
CORRECTING and REPLACING ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential... Jun 16 2014
IMMUNOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 16 2014
Immunogen upgraded by UBS Jun 12 2014
Will This Analyst Upgrade Help Immunogen (IMGN) Stock Today? Jun 12 2014
Data on ImmunoGen/Sanofi's SAR3419 Jun 02 2014
ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data with Sanofi’s SAR3419 in... Jun 01 2014
ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 50th Annual Meeting of ASCO May 14 2014
IMMUNOGEN INC Financials May 09 2014
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences May 06 2014
IMMUNOGEN INC Files SEC form 10-Q, Quarterly Report May 02 2014
IMMUNOGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement Apr 29 2014
In Line Q3 Loss at ImmunoGen Apr 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide